Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Rating of “Buy” by Analysts

Royalty Pharma plc (NASDAQ:RPRX) has been assigned a consensus rating of “Buy” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $42.50.

Several research analysts have issued reports on the company. Morgan Stanley began coverage on Royalty Pharma in a report on Friday, May 16th. They issued an “overweight” rating and a $51.00 price target on the stock. Wall Street Zen lowered Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th.

Hedge Funds Weigh In On Royalty Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. boosted its position in shares of Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company’s stock worth $432,862,000 after buying an additional 5,069,127 shares during the period. Norges Bank acquired a new position in Royalty Pharma during the fourth quarter valued at $124,498,000. Victory Capital Management Inc. lifted its stake in Royalty Pharma by 270.4% in the 1st quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company’s stock worth $112,788,000 after acquiring an additional 2,644,923 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Royalty Pharma during the 4th quarter worth about $41,959,000. Finally, AQR Capital Management LLC boosted its position in Royalty Pharma by 187.0% during the 4th quarter. AQR Capital Management LLC now owns 1,903,676 shares of the biopharmaceutical company’s stock worth $48,563,000 after acquiring an additional 1,240,384 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock opened at $32.45 on Friday. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $34.32. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a market cap of $18.71 billion, a PE ratio of 22.38, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. The company’s 50-day moving average price is $32.40 and its two-hundred day moving average price is $30.17.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The business had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. As a group, sell-side analysts anticipate that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma’s dividend payout ratio is 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.